Member Info for Jarv55

Roger have you got the Nice link for that please did try searching but couldn't find it.

So they will be drilling using 2d data must be confident.

Scope of work completed

1. Geophysical Works

? 2D Seismic Reprocessing

? FTG and Magnetic Data Review & Interpretation

2. Geological Works

? Geochemistry study (analogue, outcrop, gas seep)

? Geological fieldwork, sampling & laboratory work

? Geoscience integrated interpretation (using Petrel)

? Play identification and prospect analysis

3. Engineering & Economics

? Conceptual Field Development Plan

? Exploration Economics

Highlights

· Proposal for SK334 PSC was received positively by PETROS on the 20th Sept 2023

· Finalized Prospecting Strategy in Limbang and Lawas. Prepared exploration work program for PSC exploration period in 2024

· Rig & Crew Selection. Approaching final sign off and commercial engagement.

Opportunity

· Assessment of Potential Targets: Actively evaluating Full Tensor Gravity (FTG) data and geological field-work results to assess additional potential targets on the eastern flank of Block SK334 (Lawas area). Early indications suggest the Lawas area may be equally prospective.

Thanks Roger bit confusing the way they worded it.

Although the Genedrive® CYP2C19 ID test is in development, the NICE Committee included its predicted performance and pricing in its clinical and economic models and a thorough review is included in the Committee Papers in the public consultation documents. The Genedrive POC test had the highest probability of being the most cost effective for all scenarios compared to lab based or other POC solutions. Since final performance data for the Genedrive® CYP2C19 ID test is not yet available; and the product has not yet been registered in the UK under UKCA marking, the NICE Committee reasonably comments that no recommendation can yet be made for clinical use. The Company is anticipating UKCA marking of the Genedrive CYP2C19 test prior to NICE's final report, currently scheduled for October. At that time, NICE will have the option to update the recommendation on the Genedrive CYP2C19-ID Kit.

UKCA marking now allows the Company to begin commercialisation in the UK, and actively engage in the DEVOTE programme (previously announced in May 2023), which will generate additional performance data in an acute care setting. This expanded dataset is required for CE marking submission, which will allow for commercialisation in the EU. Submission is expected in the first half of 2024 once genedrive's engagement with DEVOTE has completed. In the United Kingdom, the Company will be selling the product through its direct sales team, and momentum for adoption is expected to be influenced by positive final NICE recommendations for CYP2C19 testing, which are expected in December 2023.

Any idea how much they are getting for these tests in the acute care test setting in the UK?

UKCA marking now allows the Company to begin commercialisation in the UK, and actively engage in the DEVOTE programme (previously announced in May 2023), which will generate additional performance data in an acute care setting. This expanded dataset is required for CE marking submission, which will allow for commercialisation in the EU. Submission is expected in the first half of 2024 once genedrive's engagement with DEVOTE has completed. In the United Kingdom, the Company will be selling the product through its direct sales team, and momentum for adoption is expected to be influenced by positive final NICE recommendations for CYP2C19 testing, which are expected in December 2023.

The best thing the company can do is actually deliver White Label like they said they would its becoming a joke here.

Https://www.investormeetcompany.com/investor/companies well you can register and find out what their future plans are .

James Cheek, incoming CEO of genedrive commented: "I am very pleased to be joining genedrive at such a pivotal time for the launch and commercialisation of new rapid Point-of-Care pharmacogenetic tests for antibiotic induced hearing loss in children and optimal treatment selection for stroke patients on the genedrive® platform. I look forward to working with the outstanding individuals at genedrive, to deliver solutions that our customers need." Well lets see what his statement says in the results.

James brings extensive commercial and operational experience at a senior level through a successful career with established diagnostic companies such as Cepheid, Beckman Coulter, and Roche Diagnostics, as well as serving as an executive board member of the British In Vitro Diagnostics Association (BIVDA). The Board believes James' experience, especially his extensive involvement in selling into the NHS, will be valuable as the Company expands its commercial footprint and opportunities within the UK and more widely.

We are also pleased to announce the appointment of Dr Gino Miele, Chief Scientific Officer at genedrive, to the Board as an Executive Director, with immediate effect. Gino has considerable experience in the development of molecular diagnostic technologies and systems and has been the R&D Director at genedrive since 2015 and its predecessor Epistem since 2011. Prior to that Gino has held associate director positions in personalised medicine at Wyeth and Pfizer. Gino has been a key driver in the development of the genedrive® system and the recent menu of pharmacogenetic tests.

I take these two could buy shares after the results are out. Or will they still be in a closed period?

Best of luck in what ever you do Pattison more to life than social media but thanks for your research appreciated.

Its a shame we trade through Aquis

Gold on the rise again.

thought i would pop into to see what the rise in sp was all about last week. and to see if there is anyone discussing the fundamentals, but no just two people ****ging each other off what a waste of time.

SHARES NOT IN PUBLIC HANDS

There are currently 16.34% of total shares not in public hands.

Last updated date: 14 November 2023.

https://www.gstechnologies.co.uk/investor-relations

Berenberg Bank reaffirmed their buy rating on shares of Pan African Resources (LON:PAF – Free Report) in a report released on Wednesday morning, MarketBeat.com reports. The brokerage currently has a GBX 25 ($0.31) price target on the stock.

Pan African Resources Price Performance

PAF stock opened at GBX 16.44 ($0.21) on Wednesday. The stock has a market capitalization of £315.65 million, a PE ratio of 544.00, a price-to-earnings-growth ratio of 8.95 and a beta of 0.75. The company’s 50-day moving average is GBX 15.40 and its 200-day moving average is GBX 14.59. The company has a debt-to-equity ratio of 19.29, a current ratio of 0.79 and a quick ratio of 0.74. Pan African Resources has a 1 year low of GBX 11.73 ($0.15) and a 1 year high of GBX 20.90 ($0.26).

The business also recently disclosed a dividend, which will be paid on Tuesday, December 12th. Stockholders of record on Thursday, November 30th will be given a dividend of GBX 0.75 ($0.01) per share. The ex-dividend date is Thursday, November 30th. This represents a dividend yield of 5.35%. Pan African Resources’s dividend payout ratio (DPR) is presently 3,333.33%.

Pan African Resources PLC engages in the mining, extraction, production, and sale of gold in South Africa. The company's flagship projects include the Barberton Mines that consists of three underground mines, including Fairview, Sheba, and Consort located in the Barberton Greenstone Belt; and Elikhulu tailings retreatment plant in Southern Africa.

https://www.defenseworld.net/2023/11/23/berenberg-bank-reaffirms-buy-rating-for-pan-african-resources-lonpaf.html

Would expect a seller tr1 27-Nov-23 18:28:32 16.542 1,665,799 Unknown* 16.90 17.08 275.56k O

27-Nov-23 17:29:59 16.54 250,775 Unknown* 16.90 17.08 41.48k O

27-Nov-23 17:29:59 17.063 148,498 Unknown* 16.90 17.08 25.34k O

27-Nov-23 16:55:25 16.541 2,630,577 Unknown* 16.90 17.08 435.12k

Who knows Pattison seems every country near buy is interested in TL China, Japan, Malaysia, the Philippines, etc.

The proposals include a potential deal with China over liquefied natural gas (LNG) in Mozambique, Canada and Australia.

https://www.middleeasteye.net/news/cop-uae-seek-oil-gas-deals-climate-talks-leaked-documents

The briefings also suggest that the UAE will use the talks to seek deals for Masdar, with additional talking points prepared for meetings with 20 countries including the UK, USA, France, Germany, the Netherlands, Brazil, China, Saudi Arabia, Egypt and Kenya

Https://en.tatoli.tl/2023/10/16/horta-and-uae-discuss-ways-to-mobilize-investors-to-invest-in-tl/19/

Recruited highly experienced Well Operations Manager

• Identified other key personnel for project execution

• Reviewing and updating well design and costs

• In discussions with rig owners and other contractors for

deployment of suitable jack-up rig

• In discussions with other regional operators to identify

potential logistical and operational cost-saving synergies

• Scheduled Drilling Planning Workshops with ANP and

TIMOR GAP

• Providing offshore training to Timorese staff

• Submitted first phase documentation to ANP for

environmental permits

Appraisal well location considerations:

• Distance from Chuditch-1 4,800m

• Quality of seismic data at target Very good

• Increased gas column predicted 133m (vs. 30m)

• Low risk on presence of best reservoir Yes

• Sufficient distance from Chuditch fault >500m at target

• Low risk drilling trajectory Vertical well

• Minimise faults along well path Limited

• Water depth and slope 60m,